Physician profile
Peter Chang
NPI 1285623009
$4,852.46
in general payments reported to CMS, 2019-2025
31 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $648 · 2021: $832 · 2022: $728 · 2023: $605 · 2024: $390 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.87 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $615.70 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $612.65 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $469.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $414.84 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $376.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.96 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $307.65 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $285.50 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $275.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $205.38 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $130.88 | 2019-2020 | |
| Boston Scientific Corporation | $116.28 | 2019-2025 | Avvigo Guidance System, Watchman Access System |
| Novo Nordisk INC | $103.71 | 2024-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $76.06 | 2025 | |
| Abiomed | $57.21 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Motiva USA, LLC | $55.92 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.08 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $38.23 | 2019 | |
| Esperion Therapeutics, INC. | $38.04 | 2020-2024 | Nexletol |
| Kiniksa Pharmaceuticals, Ltd. | $37.66 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.27 | 2020 | |
| Gilead Sciences, INC. | $29.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $28.43 | 2021 | |
| Inspire Medical Systems, INC. | $22.91 | 2024 | Inspire |
| Bardy Diagnostics, INC. | $22.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $19.90 | 2025 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $19.36 | 2021 | |
| Kestra Medical Technology Services, INC. | $16.05 | 2025 | Assure Wcd |
| Azurity Pharmaceuticals, INC. | $14.34 | 2025 | Edarbi |
| Tolmar, INC. | $13.56 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.